

RESEARCH

Open Access



Combination antimicrobial therapy: in vitro synergistic effect of anti-staphylococcal drug oxacillin with antimicrobial peptide nisin against *Staphylococcus epidermidis* clinical isolates and *Staphylococcus aureus* biofilms

Toktam Sharafi^{1,2}, Ezzat Allah Ghaemi^{1,2}, Maryam Rafiee^{1,2} and Abdollah Ardebili^{1,2*} 

Abstract

The ability of *Staphylococcus epidermidis* and *S. aureus* to form strong biofilm on plastic devices makes them the major pathogens associated with device-related infections (DRIs). Biofilm-embedded bacteria are more resistant to antibiotics, making biofilm infections very difficult to effectively treat. Here, we evaluate the in vitro activities of anti-staphylococcal drug oxacillin and antimicrobial peptide nisin, alone and in combination, against methicillin-resistant *S. epidermidis* (MRSE) clinical isolates and the methicillin-resistant *S. aureus* ATCC 43,300. The minimum inhibitory concentrations (MIC) and minimum biofilm eradication concentrations (MBEC) of oxacillin and nisin were determined using the microbroth dilution method. The anti-biofilm activities of oxacillin and nisin, alone or in combination, were evaluated. In addition, the effects of antimicrobial agents on the expression of *icaA* gene were examined by quantitative real-time PCR. MIC values for oxacillin and nisin ranged 4–8 µg/mL and 64–128 µg/mL, respectively. Oxacillin and nisin reduced biofilm biomass in all bacteria in a dose-dependent manner and this inhibitory effect was enhanced with combinatorial treatment. MBEC ranges for oxacillin and nisin were 2048–8192 µg/mL and 2048–4096 µg/mL, respectively. The addition of nisin significantly decreased the oxacillin MBECs from 8- to 32-fold in all bacteria. At the 1× MIC and 1/2× MIC, both oxacillin and nisin decreased significantly the expression of *icaA* gene in comparison with untreated control. When two antimicrobial agents were combined at 1/2× MIC concentration, the expression of *icaA* were significantly lower than when were used alone. Nisin/conventional oxacillin combination showed considerable anti-biofilm effects, including inhibition of biofilm formation, eradication of mature biofilm, and down-regulation of biofilm-related genes, proposing its applications for treating or preventing staphylococcal biofilm-associated infections, including device-related infections.

Keywords Antimicrobial peptide, Biofilm inhibition, MRSA, MRSE, Nisin, *icaA*

*Correspondence:

Abdollah Ardebili
aardebili2014@gmail.com

¹Infectious Disease Research Center, Faculty of Medicine, Golestan
University of Medical Sciences, Gorgan, Iran

²Department of Microbiology, Faculty of Medicine, Golestan University of
Medical Sciences, Gorgan, Iran



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Biofilms are complex communities of bacteria attached to and embedded in a matrix composed of extracellular polymeric substances (EPS) [1]. The matrix is mainly composed of exopolysaccharides, proteins, lipids, nucleic acids (eDNA and eRNA), and other biomolecules [1, 2]. EPS play major structural and functional roles that have crucial importance in the emergent properties of biofilms. EPS primarily strengthen microbial attachment to biological and abiotic surfaces. Then, further production of EPS forms a matrix that encloses and holds the cells firmly together, keeping them in close proximity and allowing intercellular interactions within a restricted space [1]. In addition, the EPS matrix also is a network that provides structural stability and functional environments that are essential for the biofilm lifestyle [3]. Likewise, EPS are responsible for enhanced tolerance or resistance of biofilm to antimicrobial agents and immune cells [2, 4].

Microorganisms within the biofilms can attach to both abiotic (e.g., almost all types of medical devices) and biotic (e.g., skin, bone, airway, connective tissue, intestinal mucosa, vascular endothelium) surfaces [5]. Therefore, biofilms may be associated with several tissue-associated chronic infections, in addition to their association with artificial surfaces [6]. Establishment of multilayered biofilm formation on medical devices results in device-related infections (DRIs) that are notoriously difficult to eradicate and often tend to relapse [7]. Under such condition, surgical removal and replacement of the device is often necessary and in cases where this is not a feasible option, patients require periodic antibiotic therapy for the remainder of their lives, causing a great morbidity and mortality [8, 9].

Although a wide range of bacterial and fungal species have been shown to cause biomedical device-related infections, *Staphylococcus epidermidis* and *S. aureus* are among the most common [10, 11]. Even, it has been suggested that *S. epidermidis* is responsible for nearly 80% of the bacteria causing medical DRIs [12]. Patients with prosthetic heart valves, cardiac devices, prosthetic joints, central lines, contact and intraocular lens, urinary and intravascular catheters, and intravenous drug use are at most risk of being infected with this member of the coagulase-negative staphylococci (CoNS) [13, 14]. A major clinical problem is that DRIs are often caused by methicillin-resistant *S. epidermidis* (MRSE), as well as multidrug-resistant (MDR) *S. epidermidis* and that the infections are naturally chronic due to formation of strong biofilm on the implanted devices, collectively hindering effective antibiotic therapy to clear infections [10, 15, 16]. The EPS molecule involved in biofilm formation in staphylococci has been named polysaccharide intracellular adhesin (PIA) based on function,

or polyb-1-6-N-acetylglucosamine (PNAG) based on its chemical nature [17]. PIA, which facilitates cell to cell adhesion, is synthesized by the *ica* (intercellular adhesion) locus containing four different genes, *icaA*, *icaD*, *icaB*, and *icaC*. Expression of all four genes, which are arranged in an operon, is required for the synthesis of fully functional PIA [17]. The presence of the *icaADBC* gene family has been reported in *S. epidermidis* isolated from medical devices [18, 19].

Due to the complicated physical and biological properties of EPS matrix, biofilm-related infections are often not managed by conventional antimicrobial approaches, necessitating multi-targeted or combinatorial therapies. Therapeutic strategies that can generally be considered include preventing biofilm formation either by inhibiting the EPS production or blocking adhesin-mediated adherence and/or degrading the EPS in developed biofilms. As class I of bacterial-origin antimicrobial peptides (bacteriocins), lantibiotics or lanthionine-containing antibiotics, are promising therapeutic candidates exploring novel antimicrobial agents [20, 21]. Lantibiotics are ribosomally synthesized and post-translationally modified bio-active peptides (RiPPs) that have efficient bactericidal ability even against highly resistant superbugs, such as vancomycin-resistant enterococci (VRE) or methicillin-resistant *S. aureus* (MRSA), *Clostridioides difficile*, and some of them showed good activity in pre-clinical studies [22]. The lantibiotic nisin is the only bacteriocin legally approved as biopreservative and is used in the dairy industry to control contamination from *Listeria* strains [21]. Because of its wide-spectrum activity against both Gram-positive and Gram-negative pathogens, nisin is approved for clinical use as an alternative to antibiotics [21, 23]. Various studies have reported the applicability of nisin in the treatment of several infections, such as mastitis, oral, respiratory, and skin infections [24]. Nisin causes bacterial growth inhibition by pores formation in microbial cytoplasmic membrane (CM) and by interrupting the cell wall (CW) biosynthesis process through specific interaction with the precursor lipid II [23–25]. In a MRSA model, nisin was also shown to be associated with cell shrinkage and chromosomal DNA condensation, indicating that nisin interferes with DNA replication or segregation in *S. aureus* [26].

Previous study demonstrated high activity of nisin against both planktonic and sessile cells of several MRSA and *S. epidermidis* clinical isolates [27]. Furthermore, several studies have found synergistic effects through combination of nisin with various antimicrobials against both planktonic state and biofilms of different bacteria, including staphylococci [28–34]. The nisin-biogel has showed inhibitory capacity against *S. aureus* isolated from diabetic foot infections either in their planktonic and biofilm forms [35], and could be applied in combination with

conventional antibiotics and antiseptics to improve their efficacy [36, 37]. With this in mind, the present study set out to evaluate the antibacterial activity of anti-staphylococcal drug oxacillin in combination with antimicrobial peptide nisin against clinical isolates of methicillin-resistant *S. epidermidis* (MRSE) and the standard strain methicillin (oxacillin)-resistant *S. aureus* ATCC 43,300 grown under routine culture conditions, biofilms, as well as biofilm-related gene *icaA*.

Materials and methods

Bacterial strains

The following bacterial strains were used in the present study: the *mecA* positive, methicillin (oxacillin)-resistant *S. aureus* (MRSA) (American Type Culture Collection ATCC® 43,300™), a reference strain originally isolated from United States, Kansas that was given as gift by Professor Mohammad Reza Pourshafie, Pasteur Institute of Iran, Tehran, and three clinical isolates of methicillin-resistant *S. epidermidis* (MRSE) that were recovered from clinical specimens by standard microbiological, biochemical, and molecular tests from a previous study [38] and then, the CLSI disk diffusion method with cefoxitin 30-μg disk (Rosco Diagnostica Co., Denmark) was used to identify methicillin resistance [39, 40]. *S. aureus* ATCC 43,300 was used as a control strain for detection of methicillin resistance, presence of the *icaA* gene, and biofilm production.

Media

Brain heart infusion (BHI) broth (Merck KGaA, Darmstadt, Germany) was used for the cultivation of bacteria employed in the preparation of inocula for minimum inhibitory concentration (MIC) and genomic DNA extraction. Cation-adjusted Mueller-Hinton (CAMH) broth (Merck KGaA, Darmstadt, Germany) was used to determine the MIC, minimum biofilm-eliminating concentration (MBEC), and to perform checkerboard test. Tryptic soy broth supplemented with 1% glucose (TSB-glucose) (Condalab, Co, Madrid, Spain) was used for examination of biofilm formation and biofilm inhibition assays.

Oxacillin and nisin preparation

Anti-staphylococcal antibiotic oxacillin sodium monohydrate (CAS#7240-38-2) and bacteriocin nisin from *Lactococcus lactis* (CAS#1414-45-5) were purchased from Sigma-Aldrich (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany). To prepare oxacillin stock solution, lyophilized oxacillin powder was dissolved in water. Nisin stock solution (10^6 IU/g) was prepared by dissolving the lyophilized powder in hydrochloric acid (20 mM) to a concentration of 0.1 g/10 mL (10^4 IU/g).

All stock solutions were stored in a freezer (-80 °C) until further use [39, 41].

MIC determination

Antimicrobial activity of oxacillin and nisin against the planktonic cells was determined by the broth microdilution (BMD) method using CAMH broth according to the clinical and laboratory standards institute (CLSI) guidelines [39]. Briefly, each agent was serially diluted into a 96-well microtiter plate (JET Biofil, Guangzhou, China) at a volume of 100 μL of CAMH broth. The overnight bacterial culture of BHI broth was diluted to reach a density of approximately 1.5×10^8 CFU/mL. The suspension was then diluted 1:20 to yield 5×10^6 CFU/mL. A 10-μL aliquot of prepared suspension was inoculated to each well with different concentrations of antimicrobials, yielding the final test concentration of bacteria approximately 5×10^5 CFU/mL. Antimicrobial activity was expressed as the MIC, the lowest concentration of each agent at which complete inhibition of bacterial growth is visually observed after 24 h of incubation at 37 °C. The experiments were performed in three independent biological replicates, each with three technical replicates.

Biofilm formation assay

Biofilm formation was examined by crystal violet staining method as described previously [42]. An overnight culture of bacterial strains was adjusted to 0.5 McFarland, and then diluted 1:100 in TSB-glucose to yield a final concentration of approximately 1×10^6 CFU/200 μL. A 200-μL aliquot was added to each well of a sterile microplate. Wells with TSB-glucose and inoculated suspension were considered negative and positive controls, respectively. After incubation at 37 °C for 24 h, contents of the wells were gently discarded and plates were washed three times with sterile phosphate-buffered saline (PBS, pH 7.3) to remove non-adherent bacteria. Adherent biofilm in each well was fixed with 99% methanol for 10 min, the solutions were removed, and the plate was dried. Biofilm in wells were stained with 200 μL 0.1% crystal violet (CV) (Merck KGaA, Darmstadt, Germany) for 5 min at room temperature, rinsed with water, and then dried. Biofilms were destained by treatment with 200 μL 95% ethanol for 30 min. Optical density (OD) of stained adherent cells was measured at 595 nm in a microtiter plate reader (BioTek, Bad Friedrichshall, Germany). Three biological replicates (each with two technical replicates) were carried out for all strains. A cut-off value (OD_{cut}) as three standard deviations (SDs) above the mean OD of the negative control was established: OD_{cut} = average OD of negative control + $(3 \times SD \text{ of ODs of negative control})$. The following criteria were used for biofilm gradation in clinical isolates: non-biofilm-producer (-) if $OD < OD_{cut}$, weak biofilm-producer (+) if $OD_{cut} < OD < 2 \times OD_{cut}$, moderate

biofilm-producer (++) if $2 \times OD_{cut} < OD < 4 \times OD_{cut}$, and strong biofilm-producer (+++) if $4 \times OD_{cut} < OD$.

Inhibition of biofilm formation assays

Activity of antibiotic or peptide alone. The ability of oxacillin or nisin to inhibit biofilm formation was investigated. Standard and clinical staphylococci were prepared at a concentration of 1×10^6 CFU/200 μ L in TSB-glucose from the overnight cultures. A 100- μ L aliquot was added to the wells of a 96-well plate containing 100 μ L of nisin or oxacillin alone at 1 $\times$, 1/2 $\times$, 1/4 $\times$, and 1/8 $\times$ MIC. The wells containing inoculated bacterial strains without peptide or antibiotic were considered positive controls. After incubation at 37 °C for 24 h, contents of the wells were discarded, microplates were washed thrice with PBS, and then biofilm was stained with CV and OD₅₉₅ was determined. The results expressed as the percentage of biofilm reduction compared with positive controls [41].

Combinatorial treatment of antibiotic and peptide. The effects of oxacillin and nisin in combinations against production of staphylococcal biofilms were evaluated by the BMD checkerboard technique with some modifications [41]. Briefly, serial dilutions of each of oxacillin and nisin were prepared and then mixed in four wells of the microplate in concentrations equivalent to 1 $\times$, 1/2 $\times$, 1/4 $\times$, and 1/8 $\times$ MIC. A 100- μ L aliquot of bacterial suspension at concentration of 1×10^6 CFU/200 μ L in TSB-glucose was added to each well containing both antibiotic and peptide. The positive controls were bacteria inoculated in TSB-glucose without antibiotic or peptide, and negative controls were medium with neither bacteria nor antimicrobial agents. After incubation, wells were rinsed three times with PBS, then the biofilm was stained with CV and OD was determined at 595 nm.

Minimum biofilm elimination concentration (MBEC) assay

Susceptibility of *Staphylococcus* established biofilms was evaluated as previously described for MBEC assay [2]. The mature biofilm in a 96-well microtiter plate was washed thrice with PBS to remove planktonic cells. Antimicrobials were serially diluted to various concentrations ranging from 128 to 65,536 μ g/mL for oxacillin and 32 to 16,384 μ g/mL for nisin in CAMH broth. A 200 μ L of each concentration was added in a corresponding well, and plates were incubated at 37°C for 24 h. The well with

established biofilm was used as the positive control and well containing CAMH broth with no peptide or antibiotic treatment was used as negative control. Then, contents of the wells were removed and wells were rinsed with sterile PBS to remove residual antimicrobials, and 200 μ L of fresh CAMH broth was added to each well and allow to additionally incubate at 37 °C for 24 h. The OD of wells was measured at 595 nm using a microplate reader. MBEC was defined as the minimum antimicrobial concentration that inhibited bacterial regrowth from the treated biofilm relative to the cell-only control.

The effect of nisin on oxacillin MBEC

The combined effect of oxacillin and nisin on biofilms was evaluated as described previously described with some modifications [2, 43]. First, the 24 h biofilms were formed in 96-well microtiter plates and washed three times with PBS. Next, bacterial biofilms were challenged with different concentrations of oxacillin ranging from 4 $\times$ to 2048 $\times$ MIC and nisin at determined MBEC concentration. Following the overnight incubation, contents of the wells were removed. Then, microplate was washed with sterile PBS, after that, 200 μ L of CAMH broth was added to wells for further 24-h incubation. Finally, MBEC of the oxacillin for biofilm cultures was determined as mentioned in “MBEC assay”.

Polymerase chain reaction (PCR) assay and sequence analysis

Using the phenol-chloroform method, genomic DNA from the cells grown in a 24-h culture of BHI broth was extracted [40]. The presence of intercellular adhesion *icaA* gene was investigated in clinical isolates of *S. epidermidis* and *S. aureus* ATCC 43,300 by conventional PCR using the specific primers listed in Table 1 [44]. Each PCR mixture contained 12.5 μ L Taq DNA Polymerase 2x Master Mix RED (Ampliqon, Odense, Denmark), including 1 $\times$ PCR buffer (Tris-HCl pH 8.5, $[NH_4]_2SO_4$, 1.5 mM $MgCl_2$, 0.2% Tween® 20), 0.2 mM of each dNTPs, and Taq DNA polymerase 5 U/ μ L), 0.5 μ L of 10 μ M forward and reverse primers (0.2 μ M), 1 μ L of template DNA (5 ng), and sterile distilled water up to 25 μ L. PCR was done in a Mastercycler gradient instrument (Eppendorf, Hamburg, Germany) with initial denaturation at 94 °C for 5 min, followed by 35 cycles of amplification (denaturation at

Table 1 Oligonucleotide primers used in cDNA synthesis and amplification by qPCR

Gene	Primer (5'→3')	Amplicon size (bp)	T _m (°C)	Reference
<i>icaA</i> (for <i>S. epidermidis</i>)	F: TGCACTCAATGAGGGAATCA R: TAACTGCGCCTAATTTTGGATT	134	56	[44]
16 S rRNA (Reference gene)	F: GGGCTACACACGTGCTACAA R: GTACAAGACCCGGGAACGTA	176	56	[44]
<i>icaA</i> (for <i>S. aureus</i> ATCC 43,300)	F: ACACTTGCTGGCGCAGTCAA R: TCTGGAACCAACATCCAACA	188	56	[72]

94 °C for 1 min, annealing at 56 °C for 1 min, and extension at 72 °C for 1 min), ending with a final extension at 72 °C for 5 min. The PCR products were electrophoresed on 2% agarose gel, visualized by DNA Safe Stain (SinaClon Bioscience Co., Tehran, Iran) and photographed under UV light. Sequencing of the PCR products was performed using reverse primer on the ABI by an ABI 3730xl DNA Analyzer (Applied Biosystem Inc., Foster City, CA, USA). The sequences were compared by the NCBI BLAST program (<http://www.ncbi.nlm.nih.gov/BLAST/>).

Gene expression analysis

Real-time quantitative reverse transcription (qRT) PCR was performed to determine the expression level of the *icaA* gene in staphylococci using the primers shown in Table 1. The *16 S rRNA* gene was used as an internal control to standardize expression levels between samples [45]. Staphylococcal cells were cultured in TSB-glucose and incubated at 37 °C for about 4 h to reach mid-exponential phase. The standardized 0.5 MacFarland bacterial suspensions were diluted 1:100 in fresh TSB-glucose. These suspensions were then transferred into each well of a 12-well tissue culture microtiter plate. At this time, 1× MIC and 1/2× MIC oxacillin, nisin, and 1/2× MIC+1/2× MIC combinations were added and incubated at 37 °C for 24 h. The wells containing bacterial suspension without peptide or antibiotic were used as controls. Wells were washed thrice with PBS, and then bacterial biofilms were harvested using the microprobe of an XL-2000 sonicator with sonication twice at amplitude 1.5 for 10 s with 1 min interval on ice (Qsonica LLC Co., Newtown, CT, USA) were harvested. The biofilm suspensions were centrifuged by centrifugation at 9,000× g 4°C, for 10 min. The pellets were resuspended in 200 µL of lysostaphin-containing TE buffer (10 mM Tris HCl, 1 mM EDTA, pH 7.0) and incubated at 37 °C for 10 min. Total RNA from the pellets was extracted using the YTA Total RNA Purification Mini Kit (Favorgen Biotech. Corp., Kaohsiung, Taiwan), according to the manufacturer's instruction. Extracted crude RNA was quantified spectrophotometrically (absorbance at 260 nm, A_{260}), and treated enzymatically with RNase-free DNase I (Fermentas, Thermo Fisher Scientific Inc., Vilnius, Lithuania) to remove contaminant genomic. RNA purity was measured by the absorbance ratio A_{260}/A_{280} . The quality of the purified RNA was also examined by 3% agarose gel electrophoresis. cDNAs were synthesized from 2.5 µg of DNase-treated RNA samples using the AccuPower® RocketScript™ RT PreMix Kit (Bioneer, Republic of Korea) and 10 pM random hexamer (dN6) (Bioneer, Republic of Korea). The resulting cDNA was used as template in the real-time PCR on an ABI Prism® 7300 instrument (Applied Biosystem Inc., Foster City, CA, USA) using the AccuPower® 2X GreenStar™ qPCR Master Mix

(Bioneer, Republic of Korea). Amplification protocol included an initial denaturation step at 95 °C for 5 min, followed by 40 cycles of 95 °C for 20 s, 60 °C for 1 min, and 95 °C for 10 min. All three biological replicates were run in three technical replicates. The no reverse transcriptase control (NRT) samples were also run to check for genomic DNA contamination. The expression level of *icaA* gene was normalized between samples using *16 S rRNA* and calculated by the $2^{-\Delta\Delta C_t}$ method. A critical threshold cycle (CT) value was used to represent *icaA* transcript quantitatively. The ΔC_t s for *icaA* transcript were calculated against that for the *16 S rRNA* reference gene. Results were obtained as the relative expression of *icaA* transcript in samples treated with nisin or oxacillin compared to that of non-treated controls.

Statistical analyses

All experiments were performed in three biological replicates, each with three technical replicates and results were expressed as mean±SD. Statistical analyses were performed using GraphPad Prism version 8.01 for Windows (GraphPad Software, La Jolla, California, USA). A one-way analysis of variance (ANOVA) followed by Tukey's honest significant test was used to calculate and compare differences in the variables, including biofilm inhibition, MBEC, as well as the expression level of the *icaA* gene between the treated samples and control. All statistical analyses were done with a confidence level of 95%, and a P -value<0.05 was considered statistically significant.

Results

Susceptibility

Cefoxitin disk testing showed the zone diameter of 0 for SE3, 19 mm for both SE1 and reference strain ATCC 43,300, and 20 mm for SE2, confirming resistance to methicillin (oxacillin). The result of in vitro activities of oxacillin and nisin against staphylococci studied are shown in Table 2. The reference strain *S. aureus* ATCC 43,300 had the accurate MIC value of 8 µg/mL described by CLSI [39]. The MRSE clinical isolates had MIC range from 4 to 8 µg/mL against oxacillin. In addition, the MIC values for nisin in reference strain and all but one clinical isolate (SE1, MIC=128 µg/mL) were 64 µg/mL.

Biofilm formation

The results of biofilm formation assay showed that all three MRSE isolates were categorized as strong biofilm-producer (+++), where the OD₅₉₅ value corresponding to the amount of stained adherent cells ranged from 2.1 to 2.8 ($P>0.05$). Similarly, the reference strain *S. aureus* ATCC 43,300 also produced a strong biofilm (OD₅₉₅=2.7±0.16).

Table 2 In vitro anti-bacterial and anti-biofilm activities of oxacillin and nisin against staphylococci studied

^a Bacterial strain	Oxacillin			Nisin		
	MIC (µg/mL)	MBEC (µg/mL)	Fold change in MBEC/MIC ratio	MIC (µg/mL)	MBEC (µg/mL)	Fold change in MBEC/MIC ratio
SE1	4	8192	2048	128	2048	16
SE2	4	8192	2048	64	2048	32
SE3	8	2048	256	64	4096	64
SA ATCC 43,300	8	4096	512	64	4096	64

MBEC: Minimum biofilm eradication concentration, MIC: Minimum inhibitory concentration

^a SA ATCC 43,300 is a *mecA*-positive, methicillin (oxacillin)-resistant *Staphylococcus aureus* (MRSA) reference strain and SE1, SE2, and SE3 were three clinical isolates of methicillin-resistant *Staphylococcus epidermidis* (MRSE)

Inhibition of biofilm formation

For determining the effect of oxacillin and nisin alone on biofilm formation, we used the quantitative microtiter plate method. As shown in the Fig. 1A and B, both agents at all MIC concentrations (1×, 1/2×, 1/4×, and 1/8× MIC) showed significant inhibitory activity against biofilm formation at 24 h compared to cells incubated in medium only ($P < 0.0001$). In addition, this effect was concentration-dependent in all groups ($P < 0.0001$). Higher doses of antimicrobial exposure remarkably prevented biofilm development (up to 79.5%±1.25 and 90.36%±0.57 by oxacillin and nisin at 1× MIC, respectively, both in SE2), whereas lower antimicrobial doses caused less biofilm inhibition (up to 18.21%±3.7 and 33.52%±3.61 by oxacillin and nisin at 1/8× MIC, respectively, both in SE3).

Combination effect of oxacillin and nisin on biofilm formation

Combination of nisin and oxacillin at four concentrations, starting from 1× MIC were tested by a checkerboard manner. Results showed biofilm biomass reduction was significantly enhanced by combinations of antimicrobials at 24 h in relation to concentrations compared to when each antimicrobial was used alone at the same concentrations (Fig. 1C). Particularly, 1/4× MIC+1/4× MIC and 1/8× MIC+1/8× MIC combinations considerably inhibited biofilm formation in SE2 isolate than the use of same concentrations of agents alone (83.17%±0.41 and 81.01%±0.81 reduction in biofilm, respectively) (Fig. 1C).

MBEC values

The results showed that all staphylococci increased considerably their resistance to both agents. Oxacillin and nisin eradicated all MRSE isolates with MBEC values ranging from 2048 to 8192 µg/mL and 2048 to 4096 µg/mL, respectively. Both agents eradicated MRSA reference strain with MBEC value of 4096 µg/mL (Table 2).

The effect of nisin on oxacillin MBEC

Addition of nisin at distinct MBEC concentration ranging from 2048 µg/mL to 8192 µg/mL significantly decreased

the oxacillin MBECs from 16- to 32-fold in MRSE and 8-fold in ATCC 43,300 reference strain, indicating the synergistic effects between the AMP and antibiotic (Table 3).

PCR-sequencing analysis

All staphylococci studied carried chromosomal *icaA* gene in PCR analysis. The 188 bp- and 134 bp-band size of amplicons were detected for the *icaA* gene in *S. aureus* ATCC 43,300 and *S. epidermidis* clinical isolates, respectively (Supplementary Information file). Sequencing data confirmed the presence of the *icaA* gene in clinical isolates and reference strain.

The effect of oxacillin and nisin on the expression of *icaA* gene

The expression level of *icaA* gene in staphylococci incubated with the oxacillin and nisin is shown in Fig. 2. The level of expression was significantly decreased during treatment with 1× MIC and 1/2× MIC of each agent alone compared with the control groups ($P < 0.0001$) (Fig. 2A and B). Treatment with oxacillin down-regulated the gene ranging from 12.99-fold (in SE1) to 32-fold (in SE2) at 1× MIC concentration and 7.94-fold (in SE1) to 14.42-fold (in SE2) at 1/2× MIC concentration, while the gene was down-regulated ranging from 44.63-fold (in SE3) to 113.77-fold (in SE2) and 20.67-fold (in SE1) to 42.5-fold (in SE2) during treatment with nisin at 1× MIC and 1/2× MIC concentrations, respectively. Notably, the reduction of *icaA* expression was significantly higher with 1/2× MIC combinatorial treatments than with oxacillin or nisin alone ($P < 0.0001$) (Fig. 2C).

Nucleotide sequence accession number

The sequences of staphylococcal *icaA* gene has been submitted to NCBI and deposited in the GenBank database under the accession numbers OR752439 and OR752440.




Fig. 1 Effect of antimicrobial agents, alone (**A**, oxacillin and **B**, nisin) and in combination (**C**), on biofilm formation in staphylococci studied. The columns represent the average values of triplicate experiments and error bars represent the standard deviations. The asterisks represent the statistical difference between the groups and the control, determined by one-way analysis of variance (ANOVA) followed by Tukey's honest significant test. Significance was accepted when the P -value was <0.05 (**** $P < 0.0001$). SA: *Staphylococcus aureus*, SE: *Staphylococcus epidermidis*, MIC: Minimum inhibitory concentration

Discussion

Generally, treatment of biofilm-related infections is very difficult due to several factors, such as the reduction of drug penetration and release by the extracellular matrix, the slow growth rate of cells in the biofilm, and the presence of silent cells [34, 46]. To overcome the biofilm-associated resistance, novel therapeutic strategies have been today of interest to develop effective antimicrobial agents against these infections [41].

Various studies have demonstrated the ability of AMPs to inhibit biofilm formation or degrade of mature bacterial biofilms [47–49]. In recent years, application of AMPs in combination with conventional antibiotics has been shown to be effective against the biofilm structures as a viable therapeutic approach [15, 41, 50, 51]. It also allows reducing the dosages, attenuating the rates of adverse events, and enhancing the selective toxicity of antibiotics [52, 53]. Here, we examined the effects of combining the prototypical lantibiotic nisin and conventional antibiotic

Table 3 The combined effects of oxacillin and nisin on MBEC values of oxacillin in staphylococci studied

^a Bacteria	MBEC value ($\mu\text{g/mL}$) of		Fold reduction in oxacillin MBEC in the presence of nisin
	Oxacillin	Oxacillin + nisin	
SE1	8192	256	32
SE2	8192	512	16
SE3	2048	128	16
SA ATCC 43,300	4096	512	8

MBEC: Minimum biofilm eradication concentration

^a SA ATCC 43,300 is a *mecA*-positive, methicillin (oxacillin)-resistant *Staphylococcus aureus* (MRSA) reference strain and SE1, SE2, and SE3 were three clinical isolates of methicillin-resistant *Staphylococcus epidermidis* (MRSE)

oxacillin on biofilm formation and/or eradication of *S. aureus* ATCC 43,300 and *S. epidermidis* clinical isolates. Furthermore, we revealed that the combinations were more effective in reducing the expression level of *icaA* gene during biofilm formation compared to when either antimicrobial is used alone.

In this study, we first evaluated the in vitro activities of antimicrobials alone against standard MRSA and clinical MRSE planktonic cells. The MICs for oxacillin and nisin ranged from 4 to 8 $\mu\text{g/mL}$ and 64 to 128 $\mu\text{g/mL}$, respectively. When we assessed the anti-biofilm activities of these antimicrobial agents, the MBEC values for oxacillin and nisin ranged between 2048 and 8192 $\mu\text{g/mL}$ and 2048 to 4096 $\mu\text{g/mL}$, respectively, indicating that mature biofilms are highly resistant to antimicrobial agents [54, 55]. Under such conditions, the dosage regimens of the clinically used antibiotics that have primarily developed for treatment of infections due to the planktonic bacteria are ineffective to eradicate their biofilms. The MBEC/MIC ratio of oxacillin and nisin in the present study ranged from 256- to 2048-fold and 16- to 64-fold, respectively, that is in line with findings obtained by studies working on different antibiotics and AMPs [15, 41, 56]. The MBEC/MIC ratio is one of the important factors for choosing the antibacterial agents in the treatment of biofilm-related infections. Although the MIC values of nisin were higher than those of oxacillin, it is noteworthy that the MBEC/MIC ratio of nisin was significantly lower than that of oxacillin ($P < 0.05$), suggesting the higher anti-biofilm effect of nisin compared to oxacillin. Okuda et al., have revealed that nisin A is significantly effective against MRSA and other staphylococcal biofilms. They found that 4 $\times$ MIC concentration of nisin A killed completely *S. aureus* MR23 during 1-h incubation. Nisin A showed also high activity against *S. aureus* MR23 biofilm as time- and dose-dependent manner. In addition, after treatment of other staphylococcal biofilms, including that of *S. epidermidis* with various bacteriocins at a concentration of 4 $\times$ MIC for 1 h, nisin A showed the highest activity, with the majority of dead cells constituting the




Fig. 2 Real-time quantitative PCR analysis of the *icaA* gene transcription in staphylococcal biofilms incubated with antimicrobial agents, alone (**A**, oxacillin and **B**, nisin) and in combination (**C**). The expression level of *icaA* was normalized to the *16S rRNA* gene. The columns represent the average values of triplicate experiments and error bars represent the standard deviations. The one-way analysis of variance (ANOVA) followed by Tukey's honest test indicated a significant difference between each of the strains and untreated groups. Significance was accepted when the *P*-value was < 0.05 . SA: *Staphylococcus aureus*, SE: *Staphylococcus epidermidis*, MIC: Minimum inhibitory concentration

biofilm. Their further experiments indicate that nisin A and other pore-forming bacteriocins might be effective for the prevention and treatment of biofilm-associated infections in clinical applications [27].

Our results showed that both oxacillin and nisin significantly inhibit biofilm formation in a dose-dependent manner ($P < 0.0001$). Notably, the maximum impact on biofilm formation was found for SE2, where 90.36% and 79.5% of 24-h biofilm was inhibited by nisin and oxacillin, respectively, at growth inhibitory concentration. Similarly, the study by Qu et al., demonstrated that biofilm of some CoNS is increased by oxacillin in a concentration-dependent manner [57]. Wang et al., showed that single oxacillin treatment at $1/2 \times$ MIC inhibited the biofilm formation in 2 out of 4 MRSA strains, while significantly stimulated on the two other MRSA studied, especially on the methicillin-sensitive *S. aureus* (MSSA) ATCC 25,923 [58]. In addition, they found that the biofilm producing in all but one MRSA strains decreased compared with control after treated with nisin at same concentration [58]. Although we didn't observe in the present study, inducing biofilm formation by oxacillin or nisin has been reported by previous studies [59–62]. Mirani et al., found that exposure to sub-MICs of methicillin led to a considerable increase in biofilm production in *S. aureus* USA300 and USA500 that was mediated by autolysis activity of *atl* [62]. This indicates that a genetic mechanism causes bacterial lysis to liberate eDNA that can enhance biofilm production [63]. Likewise, Sudagidan and Yemenicioğlu observed that nisin at MIC concentration (25 µg/mL) reduced or inhibited biofilm formation in all *S. aureus* strains, but some of them continued to form biofilm at sub-inhibitory concentrations [64]. These studies suggest a strain-dependent resistance among *Staphylococcus* spp. to oxacillin and other related compounds, as well as nisin.

In the present study, oxacillin+nisin treatment could effectively inhibit biofilm formation compared to single treatments. Mataraci and Dosler demonstrated that treatment of MRSA ATCC 43,300 biofilms in vitro with nisin improves the efficacy of daptomycin, linezolid, teicoplanin, azithromycin, and ciprofloxacin in bacterial killing than antibiotic treatment alone [41]. The results of study by Field et al., revealed that sub-inhibitory levels ($1/5 \times$ MIC and $1/4 \times$ MIC for colistin and nisin, respectively) can effectively prevent biofilm formation in *Pseudomonas aeruginosa* PAO1 through total inhibition of growth, thereby enhancing efficacy, and ultimately, restoring sensitivity [53]. Beta-lactam antibiotics (e.g., oxacillin) target bacterial CW biosynthesis. When the bacteria are exposed to oxacillin, bacterial wall morphology changes, whereas in combination with nisin, morphological changes also occur in both bacterial CM and CW that facilitates nisin penetration into the bacterial cell [65, 66]. This mechanism explains how AMPs act in synergy with conventional antibiotics against planktonic cells. But, what about for biofilms? The physiochemical properties of non-living surface, such as hydrophobicity, roughness, and a predisposition to protein adsorption

play generally an important role in attachment of microorganisms to surfaces and the subsequent biofilm development [67]. Furthermore, adhesion is thermodynamically considered favorable only if the process results in a decrease in total free energy [68]. Pimentel-Filho et al., have showed that bacteriocins (e.g., nisin and bovicin HC5) change the hydrophobicity of polystyrene surfaces, causing decrease in bacterial attachment. Since the total free energy of adhesion between the surface and the bacterial cell is positive, in the medium containing bacteriocins, the adhesion process is considered unfavorable, indicating the second reason for biofilm inhibition [68]. Collectively, these findings highlight that combinations of antimicrobial agents have greater potential than single treatments to prevent biofilm formation, and at the same time suggesting a potentially synergistic effect of nisin with oxacillin.

Considering the important role of *icaA* gene in PIA synthesis and biofilm development in staphylococci [69], we assessed its transcription level as an index of biofilm formation by real-time PCR. Our results indicated that the expression was down-regulated when staphylococcal biofilms were treated by either nisin or oxacillin alone at both $1 \times$ MIC and $1/2 \times$ MIC concentrations compared to controls ($P < 0.0001$), supporting the microtiter plate method findings. These results are in agreement with those reported by Zhu et al., who found that human β -defensin 3 (H β D3) significantly decreased as dose-dependent manner the expression of both *icaA* and *icaD* genes in MRSE ATCC 35,984 [70]. Similarly, Saising et al., demonstrated that gallidermin inhibits not only the growth of staphylococci in a dose-dependent manner but also effectively prevents biofilm formation by both *S. aureus* and *S. epidermidis*. They found that the effect of gallidermin on biofilm was due to repression of biofilm-related genes *icaA* and *atlA* (major autolysin). These data imply that biofilm inhibition depend on reduced PNAG synthesis, a significant component of the staphylococcal biofilm matrix [48]. In contrast, Mirzaie et al., reported that expression of *icaA* and *atlE* genes were up-regulated in *S. epidermidis* against sub-MIC concentrations of cloxacillin, cefazolin, and clindamycin, suggesting antibiotic-induced biofilm development. However, vancomycin was able to down-regulate *icaA* and *atlE* [60]. Notably, we found that the reduction of *icaA* expression was significantly more pronounced when the bacteria were exposed to the combination of two antimicrobial agents at $1/2 \times$ MIC concentrations ($P < 0.0001$). Minich et al., found that oxacillin at the $1/2 \times$ MIC concentration decreased the relative mRNA expression of *icaA* in the biofilm-producing strain *S. epidermidis* RP62A comparison to untreated control ($p < 0.01$). In the presence of oxacillin ($1/2 \times$ MIC) and vanillin ($1/20 \times$ MIC), *icaA* expression decreased by 55% ($P < 0.0001$), highlighting the advantages of

combinatorial strategy in repressing the biofilm determinant genes [71].

Conclusions

The data presented here demonstrates the potential for nisin and conventional antibiotic combinations to act as potent antimicrobial and anti-biofilm agents against MDR pathogens, including *S. epidermidis* and *S. aureus* which form biofilm on in-dwelling devices or hospital equipment and have been shown to be the most common pathogens associated with DRIs. The enhanced anti-biofilm activity of nisin/oxacillin combinations found here against staphylococci suggests their future applications as novel approach to eliminate problematic biofilms and associated infections. It is expected that future researches will provide vital new information towards the understanding all aspects of this new strategy in the clinical applications.

Abbreviations

ANOVA	One-way analysis of variance
ATCC	American Type Culture Collection
BMD	Broth microdilution
BHI	Brain heart infusion
CAMH broth	Cation-adjusted Mueller-Hinton broth
CLSI	Clinical and laboratory standards institute
CM	Cytoplasmic membrane
CoNS	Coagulase-negative staphylococci
CT	Critical threshold cycle
CV	Crystal violet
CW	Cell wall
DRIs	Device-related infections
EPS	Extracellular polymeric substances
HβD3	Human β-defensin 3
ica	Intercellular adhesion
MBEC	Minimum biofilm-eliminating concentration
MDR	Multidrug-resistant
MIC	Minimum inhibitory concentration
MRSA	Methicillin-resistant <i>S. aureus</i>
MRSE	Methicillin-resistant <i>S. epidermidis</i>
NRT	No reverse transcriptase control
OD	Optical density
OD _{cut}	Optical density cut-off value
PBS	Phosphate-buffered saline
PCR	Polymerase chain reaction
PIA	Polysaccharide intracellular adhesion
PNAG	Polyb-1-6-N-acetylglucosamine
dN6	Random hexamer
RiPPs	Ribosomally synthesized and post-translationally modified bio-active peptides
qRT PCR	Real-time quantitative reverse transcription PCR
TSB-glucose	Tryptic soy broth with 1% glucose
VRE	Vancomycin-resistant enterococci

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12941-024-00667-6>.

Supplementary Material 1

Acknowledgements

The authors would like to thank all colleagues at the Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran, for their laboratory cooperation.

Author contributions

AA and TS conceptualized and designed study, performed the experiments, interpreted results, and analyzed data. AA and MR drafted the manuscript and AA critically revised it. EG helped in setting of the laboratory experiments, interpretation of results, analysis of data, and drafting the manuscript. All authors read and approved the final manuscript.

Funding

This work was financially supported by the research deputy of Golestan University of Medical Sciences, Gorgan, Iran, with grant number 110065.

Data availability

The datasets generated and analyzed during this research were included in the main document of this manuscript.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Golestan University of Medical Sciences with ethical code number IR.GOUMS.REC.1397.087. The experiments were performed on previously isolated bacteria from clinical specimens of hospitalized patients. The patients did not directly participate in this research work.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 27 September 2023 / Accepted: 4 January 2024

Published online: 20 January 2024

References

1. Flemming H-C, Wingender J, Szewzyk U, Steinberg P, Rice SA, Kjelleberg S. Biofilms: an emergent form of bacterial life. *Nat Rev Microbiol*. 2016;14(9):563–75.
2. Kamali E, Jamali A, Izanloo A, Ardebili A. In vitro activities of cellulase and ceftazidime, alone and in combination against *Pseudomonas aeruginosa* biofilms. *BMC Microbiol*. 2021;21:1–10.
3. Koo H, Yamada KM. Dynamic cell–matrix interactions modulate microbial biofilm and tissue 3D microenvironments. *Curr Opin Cell Biol*. 2016;42:102–12.
4. Singh S, Datta S, Narayanan KB, Rajnish KN. Bacterial exo-polysaccharides in biofilms: role in antimicrobial resistance and treatments. *J Genet Eng Biotechnol*. 2021;19(1):1–19.
5. Wi YM, Patel R. Understanding biofilms and novel approaches to the diagnosis, prevention, and treatment of medical device-associated infections. *Infect Dis Clin*. 2018;32(4):915–29.
6. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. *Nat Rev Microbiol*. 2004;2(2):95–108.
7. McCann MT, Gilmore BF, Gorman SP. Staphylococcus epidermidis device-related infections: pathogenesis and clinical management. *J Pharm Pharmacol*. 2008;60(12):1551–71.
8. Costerton W, Veoh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. *J Clin Invest*. 2003;112(10):1466–77.
9. Rohde H, Mack D, Christner M, Burdelski C, Franke G, Knobloch JK. Pathogenesis of staphylococcal device-related infections: from basic science to new diagnostic, therapeutic and prophylactic approaches. *Rev Res Med Microbiol*. 2006;17(2):45–54.
10. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. *Clin Microbiol Rev*. 2014;27(4):870–926.
11. Götz F. *Staphylococcus* and biofilms. *Mo Microbiol*. 2002;43(6):1367–78.

12. Von Eiff C, Heilmann C, Peters G. New aspects in the molecular basis of polymer-associated infections due to staphylococci. *Eur J Clin Microbiol Infect Dis*. 1999;18:443–46.
13. Cheung GY, Otto M. Understanding the significance of *Staphylococcus epidermidis* bacteremia in babies and children. *Curr Opin Infect Dis*. 2010;23(3):208.
14. Widerström M. Significance of *Staphylococcus epidermidis* in health care-associated infections, from contaminant to clinically relevant pathogen: this is a wake-up call! *J Clin Microbiol*. 2016;54(7):1679–81.
15. Mirzaei R, Alikhani MY, Arciola CR, Sedighi I, Yousefimashouf R, Bagheri KP. Prevention, inhibition, and degradation effects of melittin alone and in combination with Vancomycin and rifampin against strong biofilm producer strains of methicillin-resistant *Staphylococcus epidermidis*. *Biomed Pharmacother*. 2022;147:112670.
16. Gill SR, Fouts DE, Archer GL, Mongodin EF, DeBoy RT, Ravel J, et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant *Staphylococcus aureus* strain and a biofilm-producing methicillin-resistant *Staphylococcus epidermidis* strain. *J Bacteriol*. 2005;187(7):2426–38.
17. Nguyen HT, Nguyen TH, Otto M. The staphylococcal exopolysaccharide PIA–Biosynthesis and role in biofilm formation, colonization, and infection. *Comput Struct Biotechnol J*. 2020;18:3324–34.
18. Arciola CR, Baldassarri L, Montanaro L. Presence of *icaA* and *icaD* genes and slime production in a collection of staphylococcal strains from catheter-associated infections. *J Clin Microbiol*. 2001;39(6):2151–6.
19. Cramton SE, Gerke C, Schnell NF, Nichols WW, Götz F. The intercellular adhesion (*ica*) locus is present in *Staphylococcus aureus* and is required for biofilm formation. *Infect Immun*. 1999;67(10):5427–33.
20. Simons A, Alhanout K, Duval RE. Bacteriocins, antimicrobial peptides from bacterial origin: overview of their biology and their impact against multidrug-resistant bacteria. *Microorganisms*. 2020;8(5):639.
21. Soltani S, Hammami R, Cotter PD, Rebuffat S, Said LB, Gaudreau H, et al. Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations. *FEMS Microbiol Rev*. 2021;45(1):fuaa039.
22. Karbalaeei-Heidari HR, Budisa N. Combating antimicrobial resistance with new-to-nature lanthipeptides created by genetic code expansion. *Front Microbiol*. 2020;11:590522.
23. Dijksteelt G, Ulrich M, Middelkoop E, Boekema B. Review: lessons learned from clinical trials using antimicrobial peptides (AMPs). *Front Microbiol*. 2021;12:616979.
24. Moretta A, Scieuzo C, Petrone AM, Salvia R, Manniello MD, Franco A, et al. Antimicrobial peptides: a new hope in biomedical and pharmaceutical fields. *Front Cell Infect Microbiol*. 2021;11:668632.
25. Gopal R, Kim YG, Lee JH, Lee SK, Chae JD, Son BK et al. Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant *Acinetobacter baumannii* strains. *Antimicrob Agents Chemother*. 2014;58(3):1622–9.
26. Jensen C, Li H, Vestergaard M, Dalsgaard A, Frees D, Leisner JJ. Nisin damages the septal membrane and triggers DNA condensation in methicillin-resistant *Staphylococcus aureus*. *Front Microbiol*. 2020;11:1007.
27. Okuda K-i, Zendo T, Sugimoto S, Iwase T, Tajima A, Yamada S, et al. Effects of bacteriocins on methicillin-resistant *Staphylococcus aureus* biofilm. *Antimicrob Agents Chemother*. 2013;57(11):5572–9.
28. Naghmouchi K, Le Lay C, Baah J, Drider D. Antibiotic and antimicrobial peptide combinations: synergistic inhibition of *Pseudomonas fluorescens* and antibiotic-resistant variants. *Res Microbiol*. 2012;63(2):101–8.
29. Brumfitt W, Salton MR, Hamilton-Miller JM. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant *Staphylococcus aureus* and Vancomycin-resistant enterococci. *J Antimicrob Chemother*. 2002;50(5):731–4.
30. Rishi P, Preet Singh A, Garg N, Rishi M. Evaluation of nisin– β -lactam antibiotics against clinical strains of *Salmonella enterica* Serovar Typhi. *J Antibiot*. 2014;67(12):807–11.
31. Tong Z, Zhang Y, Ling J, Ma J, Huang L, Zhang L. An in vitro study on the effects of nisin on the antibacterial activities of 18 antibiotics against *Enterococcus faecalis*. *PLoS ONE*. 2014;9(2):e89209.
32. Field D, Gaudin N, Lyons F, O'Connor PM, Cotter PD, Hill C, et al. A bioengineered nisin derivative to control biofilms of *Staphylococcus pseudintermedius*. *PLoS ONE*. 2015;10(3):e0119684.
33. Santativongchai P, Tulayakul P, Jeon B. Enhancement of the antibiofilm activity of nisin against *Listeria monocytogenes* using food plant extracts. *Pathogens*. 2023;12(3):444.
34. Field D, O'Connor R, Cotter PD, Ross RP, Hill C. In vitro activities of nisin and nisin derivatives alone and in combination with antibiotics against *Staphylococcus aureus* biofilms. *Front Microbiol*. 2016;18:7508.
35. Santos R, Gomes D, Macedo H, Barros D, Tibério C, Veiga AS, et al. Guar gum as a new antimicrobial peptide delivery system against diabetic foot ulcers *Staphylococcus aureus* isolates. *J Med Microbiol*. 2016;65(10):1092–9.
36. Santos R, Ruza D, Cunha E, Tavares L, Oliveira M. Diabetic foot infections: application of a nisin-biogel to complement the activity of conventional antibiotics and antiseptics against *Staphylococcus aureus* biofilms. *PLoS ONE*. 2019;14(7):e0220000.
37. Gomes D, Santos R, Soares S, Reis R, Carvalho S, Rego S, Peleteiro PC, Tavares M, Oliveira L. Pexiganan in combination with nisin to control polymicrobial diabetic foot infections. *Antibiotics*. 2020;9(3):128.
38. Kord M, Ardebili A, Jamal M, Jahanbakhsh R, Behnampour N, Ghaemi EA. Evaluation of biofilm formation and presence of *ica* genes in *Staphylococcus epidermidis* clinical isolates. *Osong Public Health Res Perspect*. 2018;9(4):160.
39. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 30th ed. CLSI supplement M100, Wayne, PA;2020.
40. Mehri H, Jahanbakhsh R, Shakeri F, Ardebili A, Behnampour N, Khodabakhshi B et al. Investigation of glycopeptide susceptibility of coagulase-negative staphylococci (CoNS) from a tertiary care hospital in Gorgan, northern Iran. *Arch Pediatr Infect Dis*. 2017;5(1).
41. Mataraci E, Dosler S. In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant *Staphylococcus aureus* biofilms. *Antimicrob Agents Chemother*. 2012;56(12):6366–71.
42. Kamali E, Jamali A, Ardebili A, Ezadi F, Mohebbi A. Evaluation of antimicrobial resistance, biofilm forming potential, and the presence of biofilm-related genes among clinical isolates of *Pseudomonas aeruginosa*. *BMC Res Notes*. 2020;13:1–6.
43. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against *Candida albicans* biofilms. *Mycoses*. 2012;55(1):80–5.
44. França A, Melo LD, Cerca N. Comparison of RNA extraction methods from biofilm samples of *Staphylococcus epidermidis*. *BMC Res Notes*. 2011;4(1):1–5.
45. Szczuka E, Jabłońska L, Kaznowski A. Effect of subinhibitory concentrations of tigecycline and ciprofloxacin on the expression of biofilm-associated genes and biofilm structure of *Staphylococcus epidermidis*. *Microbiology*. 2017;163(5):712–8.
46. Batoni G, Maisetta G, Esin S. Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. *Biochim Biophys Acta Biomembr*. 2016;1858(5):1044–60.
47. Tajbakhsh M, Akhavan MM, Fallah F, Karimi A. A recombinant snake cathelicidin derivative peptide: antibiofilm properties and expression in *Escherichia coli*. *Biomolecules*. 2018;8(4):118.
48. Saising J, Dube L, Ziebandt A-K, Voravuthikunchai SP, Nega M, Götz F. Activity of gallidermin on *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms. *Antimicrob Agents Chemother*. 2012;56(11):5804–10.
49. Dean SN, Bishop BM, Van Hoek ML. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against *Staphylococcus aureus*. *BMC Microbiol*. 2011;11(1):1–13.
50. Angelopoulou A, Field D, Pérez-Ibarreche M, Warda AK, Hill C, Ross RP. Vancomycin and Nisin A are effective against biofilms of multi-drug resistant *Staphylococcus aureus* isolates from human milk. *PLoS ONE*. 2020;15(5):e0233284.
51. Bardbari AM, Arabestani MR, Karami M, Keramat F, Aghazadeh H, Alikhani MY, et al. Highly synergistic activity of melittin with imipenem and colistin in biofilm inhibition against multidrug-resistant strong biofilm producer strains of *Acinetobacter baumannii*. *Eur J Clin Microbiol Infect Dis*. 2018;37:443–54.
52. Ardebili A, Izanloo A, Rastegar M. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? *Expert Rev Anti Infect Ther*. 2023;21(4):387–429.
53. Field D, Seising N, Cotter PD, Ross RP, Hill C. Synergistic nisin-polymyxin combinations for the control of *Pseudomonas* biofilm formation. *Front Microbiol*. 2016;7:1713.
54. Maisetta G, Grassi L, Di Luca M, Bombardelli S, Medici C, Brancatisano FL, et al. Anti-biofilm properties of the antimicrobial peptide temporin 1 tb and its ability, in combination with EDTA, to eradicate *Staphylococcus epidermidis* biofilms on silicone catheters. *Biofouling*. 2016;32(7):787–800.
55. Koch JA, Pust TM, Cappellini AJ, Mandell JB, Ma D, Shah NB, et al. *Staphylococcus epidermidis* biofilms have a high tolerance to antibiotics in periprosthetic joint infection. *Life*. 2020;10(11):253.

56. Dosler S, Mataraci E. In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant *Staphylococcus aureus* biofilms. *Peptides*. 2013;49:53–8.
57. Qu Y, Daley AJ, Istivan TS, Garland SM, Deighton MA. Antibiotic susceptibility of coagulase-negative staphylococci isolated from very low birth weight babies: comprehensive comparisons of bacteria at different stages of biofilm formation. *Ann Clin Microbiol Antimicrob*. 2010;9:1–12.
58. Wang J, Ma X, Li J, Shi L, Liu L, Hou X, et al. The synergistic antimicrobial effect and mechanism of nisin and oxacillin against methicillin-resistant *Staphylococcus aureus*. *Int J Mol Sci*. 2023;24(7):6697.
59. Weiser J, Henke HA, Hector N, Both A, Christner M, Büttner H, et al. Sub-inhibitory tigecycline concentrations induce extracellular matrix binding protein embp dependent *Staphylococcus epidermidis* biofilm formation and immune evasion. *Int J Med Microbiol*. 2016;306(6):471–8.
60. Mirzaei R, Yousefimasouf R, Arabestani MR, Sedighi I, Alikhani MY. The issue beyond resistance: Methicillin-resistant *Staphylococcus epidermidis* biofilm formation is induced by subinhibitory concentrations of cloxacillin, cefazolin, and clindamycin. *PLoS ONE*. 2022;17(11):e0277287.
61. Cerca N, Martins S, Sillankorva S, Jefferson KK, Pier GB, Oliveira R, et al. Effects of growth in the presence of subinhibitory concentrations of dicloxacillin on *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* biofilms. *Appl Environ Microbiol*. 2005;71(12):8677–82.
62. Mirani ZA, Aziz M, Khan MN, Lal I, ul Hassan N, Khan SI. Biofilm formation and dispersal of *Staphylococcus aureus* under the influence of oxacillin. *Microb Pathog*. 2013;61:66–72.
63. Kaplan JB, Izano EA, Gopal P, Karwacki MT, Kim S, Bose JL, et al. Low levels of β -lactam antibiotics induce extracellular DNA release and biofilm formation in *Staphylococcus aureus*. *mBio*. 2012;3(4):10.
64. Sudagidan M, Yemencioğlu A. Effects of Nisin and lysozyme on growth inhibition and biofilm formation capacity of *Staphylococcus aureus* strains isolated from raw milk and cheese samples. *J Food Prot*. 2012;75(9):1627–33.
65. Alves FCB, Albano M, Andrade BFMT, Chechi JL, Pereira AFM, Furlanetto A, et al. Comparative proteomics of methicillin-resistant *Staphylococcus aureus* subjected to synergistic effects of the lantibiotic nisin and oxacillin. *Microb Drug Resist*. 2020;26(3):179–89.
66. Hancock RE, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol*. 2006;24(12):1551–7.
67. Araújo EA, Bernardes PC, Andrade NJ, Fernandes PE, Sá JPN. Gibbs free energy of adhesion of *Bacillus cereus* isolated from dairy plants on different food processing surfaces evaluated by the hydrophobicity. *Int J Food Sci Technol*. 2009;44(12):2519–25.
68. de Pimentel-Filho J, de Freitas Martins N, Nogueira MC, Mantovani GB, Vanetti HC. Bovicin HC5 and Nisin reduce *Staphylococcus aureus* adhesion to polystyrene and change the hydrophobicity profile and Gibbs free energy of adhesion. *Int J Food Microbiol*. 2014;190:1–8.
69. Kirmusaoğlu S. Staphylococcal biofilms: Pathogenicity, mechanism and regulation of biofilm formation by quorum sensing system and antibiotic resistance mechanisms of biofilm embedded microorganisms. In: *Microbial biofilms: importance and applications*.
70. Zhu C, Tan H, Cheng T, Shen H, Shao J, Guo Y, et al. Human β -defensin 3 inhibits antibiotic-resistant *Staphylococcus* biofilm formation. *J Surg Res*. 2013;183(1):204–13.
71. Minich A, Lišková V, Kormanová L, Krahulec J, Šarkanová J, Mikulášová M, et al. Role of RNAlII in resistance to Antibiotics and Antimicrobial agents in *Staphylococcus epidermidis* Biofilms. *Int J Mol Sci*. 2022;23(19):11094.
72. Piechota M, Kot B, Frankowska-Maciejewska A, Gruzewska A, Woźniak-Kosek A. Biofilm formation by methicillin-resistant and methicillin-sensitive *Staphylococcus aureus* strains from hospitalized patients in Poland. *Biomed Res Int*. 2018;4657396.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.